Project Grant HT94252410607
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Bloomington, IN 47405, USA
Similar Awards
This $1,261,143 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Indiana University to exploit metabolic reprogramming of prostate cancer for new therapeutics. The key research tasks include: Determining the mechanism of p53 expression activation following loss of GCN2 in prostate cancer cell lines. Evaluating the effects on gene expression and metabolism when p53 is lost in GCN2-inhibited prostate...
This Project Grant award of $468,672 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The primary awardee, Georgia College & State University, is conducting research through the Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium. The project aims to examine health-seeking behaviors, decision-making, psychosocial effects, and coping mechanisms among Black men diagnosed with prostate...
The Defense Health Agency has awarded a $1,489,868 Project Grant to the Trustees of Indiana University, doing business as Indiana University, for the "OVARIAN CANCER ACADEMY: ADVANCING OVARIAN CANCER RESEARCH THROUGH MENTORSHIP, NETWORKING, AND COLLABORATIONS" program under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, with a performance period from September 30, 2025 to September 29, 2029, will support advanced biomedical research...
This $1,319,487 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), aims to research strategies for improving prostate cancer treatment and outcomes in patients with diabetes. The Beckman Research Institute of the City of Hope, a nonprofit medical research organization, will conduct this project. The key objectives are to investigate diabetes-associated radioresistance and identify interventions to...
The Defense Health Agency awarded a $1,346,633 Project Grant to the George Washington University under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research titled "A PRIMARY ROLE FOR THE CIRCULATORY MICROENVIRONMENT IN AFRICAN AMERICAN PROSTATE CANCER DISPARITIES?" from May 15, 2023 to May 14, 2026. As the prime awardee, George Washington University will investigate medical solutions for prostate cancer disparities affecting African...
This federal Project Grant award of $1,235,845.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The project, awarded to the University of Illinois on August 15, 2025, will leverage data science methods to transform healthcare for military service members and the broader public. The funding will...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,188,750.00 to the Trustees of Indiana University, doing business as Indiana University, to support research on "Ancestry-Dependent Stromal Cell Factors in Breast Cancer Progression". The research will be conducted in Bloomington, IN from January 31, 2025 through January 30, 2028. This grant is part of the Military Medical...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This $260,250 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research on the role of the SLC45A3-ELK4 chimera as a molecular determinant of prostate cancer health disparities. The primary awardee, Health Research, Inc., will conduct this biomedical research at their Roswell Park Division facility in Buffalo, New York over a 2-year period from March 2025 to March 2027. The research aims to advance understanding...